{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:39Z","timestamp":1790796939815,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resistant chronic migraine (CM) is sparse.\u00a0<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a two-year real-world prospective analysis of an ongoing single centre audit conducted in patients with resistant CM. Patients received monthly erenumab for six months before assessing its effectiveness. Responders were considered those who achieved at least 30% reduction in monthly migraine days (MMD) by month 6, compared to baseline. Secondary outcomes were also analysed, including changes of the Headache Impact Test version 6 (HIT-6).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred sixty-four patients [135 (82.3%) females; mean age 46 SD 14) years] were included in the audit and 160 patients analysed. Patients had failed a mean of 8.4 preventive treatments at baseline. At month 6, 76 patients (48%) were 30% responders to erenumab, 50 patients (31%) were 50% responders and 25 (15%) were 75% responders. The mean reduction in MMD at month 6 was 7.5\u00a0days compared to baseline (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). At month 12 and month 18, 61 patients (38%) and 52 patients (33%) remained 30% responders respectively. At month 24, 36 patients (23%) remained 30% responders, 25 patients (16%) and 13 patients (8%) were respectively 50% and 75% responders. Compared to 95% of patients at baseline, at months 6, 12 and 24, 46%, 29% and 16% of responders respectively had severe disability. At least one adverse event at month 6, 12, 18 and 24 was reported by 49%, 19%, 11% and 3% of patients. By month 6, 13% of patients discontinued the treatment because of side effects, often constipation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Long-term sustained effectiveness of erenumab was reported only by a minority of resistant CM patients. Although more research in resistant migraine is needed, Erenumab can provide long-term meaningful reduction in migraine load and migraine-related disability in some patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01507-8","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:03:37Z","timestamp":1667556217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna P.","family":"Andreou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fuccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Kilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"issue":"10","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14656566.2022.2088281","volume":"23","author":"M Fitzek","year":"2022","unstructured":"Fitzek M, Raffaelli B, Reuter U (2022) Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. Expert Opin Pharmacother 23(10):1143\u20131153. https:\/\/doi.org\/10.1080\/14656566.2022.2088281","journal-title":"Expert Opin Pharmacother"},{"key":"1507_CR2","doi-asserted-by":"publisher","unstructured":"Schulman E. (2013) Refractory migraine - a review Headache 53(4):599-613 https:\/\/doi.org\/10.1111\/head.12047.","DOI":"10.1111\/head.12047"},{"issue":"1","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine\u202f: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA) The journal of headache and pain. J Headache Pain 21(1):76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"issue":"3","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"6","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"10203","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/s0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet (London, England) 394(10203):1030\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(19)31946-4","journal-title":"Lancet (London, England)"},{"issue":"10","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/s1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology 19(10):814\u201325. https:\/\/doi.org\/10.1016\/s1474-4422(20)30279-9","journal-title":"The Lancet Neurology"},{"issue":"1","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A et al (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23(1):61. https:\/\/doi.org\/10.1186\/s10194-022-01433-9","journal-title":"J Headache Pain"},{"issue":"1","key":"1507_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"1","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G et al (2020) Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain 21(1):102. https:\/\/doi.org\/10.1186\/s10194-020-01171-w","journal-title":"J Headache Pain"},{"issue":"5","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u201325. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"issue":"5","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/head.14313","volume":"62","author":"M Ashina","year":"2022","unstructured":"Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M et al (2022) Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. Headache 62(5):624\u2013633. https:\/\/doi.org\/10.1111\/head.14313","journal-title":"Headache"},{"issue":"3","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","volume":"93","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Reuter U, Goadsby PJ, da Silva Paiva, Lima G, Mondal S, Wen S et al (2022) Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psychiatry 93(3):254\u201362. https:\/\/doi.org\/10.1136\/jnnp-2021-327480","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1507_CR14","doi-asserted-by":"publisher","first-page":"175628642092711","DOI":"10.1177\/1756286420927119","volume":"13","author":"AP Andreou","year":"2020","unstructured":"Andreou AP, Fuccaro M, Lambru G (2020) The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord 13:1756286420927119. https:\/\/doi.org\/10.1177\/1756286420927119","journal-title":"Ther Adv Neurol Disord"},{"key":"1507_CR15","volume-title":"Erenumab for preventing migraine. Technology appraisal guidance","author":"National Institute for Health and Care Excellence","year":"2021","unstructured":"National Institute for Health and Care Excellence (2021) Erenumab for preventing migraine. Technology appraisal guidance (https:\/\/www.nice.org.uk\/guidance\/ta682)"},{"key":"1507_CR16","unstructured":". http:\/\/ www.hra-decisiontools.org.uk\/research\/."},{"key":"1507_CR17","doi-asserted-by":"publisher","unstructured":"Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 3rd edition (beta version). Cephalalgia 2013; 33: 629\u2013808.\u00a0https:\/\/doi.org\/10.1177\/0333102413485658.","DOI":"10.1177\/0333102413485658"},{"issue":"3","key":"1507_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","volume":"146","author":"RH Dworkin","year":"2009","unstructured":"Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P et al (2009) Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 146(3):238\u2013244. https:\/\/doi.org\/10.1016\/j.pain.2009.08.019","journal-title":"Pain"},{"issue":"22","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/wnl.0000000000012029","volume":"96","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, da Silva Paiva, Lima G, Hours-Zesiger P, Fernandes C et al (2021) Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study. Neurology 96(22):e2724-35. https:\/\/doi.org\/10.1212\/wnl.0000000000012029","journal-title":"Neurology"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/tcrm.s263825","volume":"18","author":"E De Matteis","year":"2022","unstructured":"De Matteis E, Sacco S, Ornello R (2022) Migraine Prevention with Erenumab: Focus on Patient Selection Perspectives and Outcomes. Ther Clin Risk Manag 18:359\u2013378. https:\/\/doi.org\/10.2147\/tcrm.s263825","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","volume":"20","author":"L D'Antona","year":"2019","unstructured":"D\u2019Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20(1):89. https:\/\/doi.org\/10.1186\/s10194-019-1040-x","journal-title":"J Headache Pain"},{"issue":"2","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain Ther 10(2):809\u2013826. https:\/\/doi.org\/10.1007\/s40122-021-00264-x","journal-title":"Pain Ther"},{"issue":"22","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","volume":"41","author":"F Schiano di Cola","year":"2020","unstructured":"Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U et al (2020) Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41(Suppl 2):489\u201390. https:\/\/doi.org\/10.1007\/s10072-020-04670-5","journal-title":"Neurol Sci"},{"issue":"7","key":"1507_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database. Cephalalgia 41(7):789\u201398. https:\/\/doi.org\/10.1177\/0333102420983292","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01507-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01507-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01507-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:03:39Z","timestamp":1667556219000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01507-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01507-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"14 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Audit under current national guidelines does not require prior research ethics committee review ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"APA received speaker honoraria and funding for travel from Allergan, Eli Lilly and eNeura, honoraria for participation in advisory boards sponsored by Allergan and Eli Lilly, sponsorship for educational purposes from eNeura, Allergan, Autonomic Technologies and Novartis, and an equipment grant from eNeura. MF, BH, and MM have nothing to declare. VC has received honoraria for participation in advisory boards sponsored by Novartis and speaker honoraria sponsored by Teva. RK has nothing to declare. GL has received speaker honoraria, funding for travel and has received honoraria for participation in advisory boards sponsored by Allergan, Novartis, Eli Lilly, TEVA and Lundbeck. He has received speaker honoraria, funding for travel from electroCore, Nevro Corp. and Autonomic Technologies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}